Shandong Xinlu Pharmaceutical Co., Ltd.

Primary objective: To evaluate the bioequivalence of the two preparations in Chinese healthy subjects in the fasting and postprandial states, using the reference preparation of Aguratimod tablets (trade name: Edexin, specification: 25 mg) produced by Hainan Xiansheng Pharmaceutical Co., Ltd. as the reference preparation and the test preparation of Aguratimod tablets (specification: 25 mg) developed by Shandong Xinlu Pharmaceutical Technology Co., Ltd. as the test preparation. Secondary objective: To observe the safety of the test preparation and the reference preparation in Chinese healthy subjects.